Dr. Scott Kopetz

Scott Kopetz, M.D., Ph.D., Associate Professor, GI Medical Oncology, University of Texas MD Anderson Cancer Center
Dr. Scott Kopetz graduated Summa Cum Laude from Vanderbilt University with a bachelor’s degree in Biomedical Engineering/Electrical and received his medical degree from Johns Hopkins School of Medicine. He obtained his residency training in Internal Medicine at Duke University Medical Center, followed by a medical oncology fellowship at MD Anderson Cancer Center. Dr. Kopetz joined MD Anderson Cancer Center in 2006 as an Assistant Professor of Medicine in the Department of Gastrointestinal Medical Oncology. He subsequently completed a Ph.D. at MD Anderson in cancer biology with thesis focus on mechanisms of chemotherapy resistance in colorectal cancer. Dr. Kopetz is board-certified in Internal Medicine and in Medical Oncology. He has authored over 100peer-reviewed articles in respected scientific journals such as Journal of Clinical Oncology, Lancet,Cancer Research, Cancer, Clinical Cancer Research, and JAMA, and is a senior editor for Clinical Cancer Research, and editorial board member on Journal of Clinical Oncology and JNCI.  He is vice chair for colon cancer research in the NSABP/RTOG cooperative group, and member of the NIH Gastrointestinal Oncology Steering Committee. In addition, he was a recipient of peer-reviewed grants from American Society of Clinical Oncology and the National Institute of Health, among others. He is the principal investigator of several Phase I and II clinical trials, including the Assessment of Targeted Therapies Against Colorectal Cancer (ATTACC) study, a novel biomarker enrichment program for colorectal cancer. His research interests include the biology of refractory colorectal cancer and the development of novel therapeutics for molecularly distinct subsets of colorectal cancer patients.